Literature DB >> 22068248

Similar clinical features among patients with severe adult growth hormone deficiency diagnosed with insulin tolerance test or arginine or glucagon stimulation tests.

Andrew Toogood1, Georg Brabant, Dominique Maiter, Björn Jonsson, Ulla Feldt-Rasmussen, Maria Koltowska-Haggstrom, Ase Krogh Rasmussen, Michael Buchfelder, Bernhard Saller, Beverly M K Biller.   

Abstract

OBJECTIVE: To determine whether insulin tolerance tests (ITTs), arginine stimulation tests (ASTs), and glucagon stimulation tests (GST) identify patients who have similar clinical features of growth hormone (GH) deficiency when a diagnostic GH threshold of 3 μg/L is used.
METHODS: Data were obtained from the KIMS database (Pfizer International Metabolic Database). Comparisons were made between patients who underwent ITT, AST, or GST for GH peak, body mass index, lipids, waist circumference, waist-to-hip ratio, and quality of life.
RESULTS: A total of 5453 tests were available from 4867 patients registered in the database (ITT = 3111, AST = 1390, GST = 952). Significant (P<.001) intraindividual correlations were observed between the GH peaks for ITT vs AST (r = 0.655), ITT vs GST (r = 0.445), and AST vs GST (r = 0.632). GH peaks in response to all tests were negatively correlated to the number of additional pituitary hormone deficiencies and positively correlated to the insulinlike growth factor 1 standard deviation score. Body mass index had a negative influence on all 3 tests. Most clinical variables did not differ between the groups when comparing GH-deficient patients according to the diagnostic test used. The only exceptions that showed any difference were body mass index (slightly higher in the AST and GST groups), triglyceride levels (increased in the GST group), and insulinlike growth factor 1 (standard deviation score) (lower in the ITT and AST groups than in the GST group). Waist circumference was greater and quality of life was worse in the GST group than in the other groups.
CONCLUSIONS: The ITT, AST, and GST produce similar GH peaks, are influenced by similar clinical factors, and identify patients with similar features of GH deficiency at a diagnostic threshold of 3 μg/L.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22068248     DOI: 10.4158/EP11146.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  5 in total

1.  Growth hormone deficiency after mild combat-related traumatic brain injury.

Authors:  Adriana G Ioachimescu; Benjamin M Hampstead; Anna Moore; Elizabeth Burgess; Lawrence S Phillips
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

2.  Can a glucagon stimulation test characterized by lower GH cut-off value be used for the diagnosis of growth hormone deficiency in adults?

Authors:  Halit Diri; Zuleyha Karaca; Yasin Simsek; Fatih Tanriverdi; Kursad Unluhizarci; Ahmet Selcuklu; Fahrettin Kelestimur
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

3.  Effects of gender, body weight, and blood glucose dynamics on the growth hormone response to the glucagon stimulation test in patients with pituitary disease.

Authors:  Jessica R Wilson; Andrea L Utz; Jessica K Devin
Journal:  Growth Horm IGF Res       Date:  2015-12-08       Impact factor: 2.372

4.  Overweight/Obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency.

Authors:  Laura E Dichtel; Kevin C J Yuen; Miriam A Bredella; Anu V Gerweck; Brian M Russell; Ariana D Riccio; Michelle H Gurel; Patrick M Sluss; Beverly M K Biller; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

5.  Copeptin under glucagon stimulation.

Authors:  Krzysztof C Lewandowski; Andrzej Lewiński; Elżbieta Skowrońska-Jóźwiak; Magdalena Stasiak; Wojciech Horzelski; Georg Brabant
Journal:  Endocrine       Date:  2015-11-17       Impact factor: 3.633

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.